Epicutaneous Immunotherapy

CHÂTILLON, France, June 29, 2026 DBV Technologies announced an update on the Biologics License Application (BLA) for its investigational...

CHÂTILLON, France, June 8, 2026 DBV Technologies announced new positive clinical findings from its Phase 3 VITESSE study evaluating...

CHÂTILLON, France and WARREN, N.J., June 2026 DBV Technologies announced that the first participant has been screened in the...